Non-oral treatment with ivermectin for disseminated strongyloidiasis.
Critically ill patients with disseminated strongyloidiasis may not be candidates for oral treatment. We report four patients with disseminated strongyloidiasis, believed to be unable to absorb oral therapy, who were treated with ivermectin by rectal and/or subcutaneous administration. Obtaining subcutaneous ivermectin and dosing it appropriately is a challenge. These cases underscore the need for improved access to subcutaneous ivermectin and more pharmacological data to guide use of this treatment approach.
Fusco
Dahlene N
DN
Division of Infectious Diseases, and Department of Surgery, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, New York, USA. dnfusco@partners.org
Downs
Jennifer A
JA
Satlin
Michael J
MJ
Pahuja
Meera
M
Ramos
Liz
L
Barie
Philip S
PS
Fleckenstein
Lawrence
L
Murray
Henry W
HW
D000285:Administration, Rectal; D000328:Adult; D000368:Aged; D000818:Animals; D000977:Antiparasitic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D007559:Ivermectin / Q000008:administration & dosage* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D013322:Strongyloidiasis / Q000188:drug therapy*
D000977:Antiparasitic Agents; D007559:Ivermectin